|

indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • University Hospital, Basel, Switzerland1

Indications

  • EBV Infections1
  • Kidney Transplant1
  • Cancer1

Other1 trial

Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.